The treatment of metabolic bone disease in patients on peritoneal dialysis.
Armstrong
A
A
Department of Nephrology, Royal London Hospital and Medical College, England, United Kingdom.
Cunningham
J
J
D017607:Aluminum Compounds / Q000009:adverse effects; D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000628:therapy*; D002119:Calcium Carbonate / Q000627:therapeutic use; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010710:Phosphates / Q000378:metabolism; D014511:Uremia / Q000150:complications*; D014807:Vitamin D / Q000627:therapeutic use
D017607:Aluminum Compounds; D010710:Phosphates; D014807:Vitamin D; D002119:Calcium Carbonate